AZ nabs breakthrough shot at FDA for new Lynparza use; Top cancer centers urge more HPV vaccine use; NICE lends backing to biosim adoption;

@FiercePharma: No obvious China baby bump for J&J as one-child policy ends. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: Novartis is revamping its manufacturing after having disposed of 25 plants. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI: U.K. cost watchdog nixes pricey biologics for moderate rheumatoid arthritis. Article | Follow @CarlyHFierce

> AstraZeneca's ($AZN) new ovarian cancer drug Lynparza got a "breakthrough" designation from the FDA for a new use in prostate cancer. Report

> Top cancer centers in the U.S. urged broader use of human papillomavirus vaccines such as GlaxoSmithKline's ($GSK) Cervarix and Merck & Co.'s ($MRK) Gardasil to prevent cancer linked to the virus. Report

> Biosimilars got a boost in Britain this week as England's cost-effectiveness watchdog said patients needing expensive biologic meds should start with "the least expensive drug." Report

> GlaxoSmithKline's consumer business in Nigeria got a buyout offer for its drinks bottling and distribution business there. Report

> Abbott Laboratories ($ABT) posted lower-than-expected quarterly sales and forecast 2016 earnings below expectations. Report

Medical Device News

@FierceMedDev: Israeli VC backed by Philips and Teva looking to invest $26M in promising med tech startups. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Sony, Carlyle Group, KKR among bidders for Toshiba's imaging unit, expected to fetch $3B+. Article | Follow @VarunSaxena2

@EmilyWFierce: Dog flu sweeps the U.S. with two more confirmed cases in Washington state. FierceAnimalHealth story | Follow @EmilyWFierce

> Investor urges J&J to spin out poor-performing device, consumer businesses. Report

> HeartWare succumbs to activist investors, calls off planned Valtech purchase. Story

> CMS draws blood, says Theranos poses 'immediate jeopardy to patient health.' Article

Biotech News

@FierceBiotech: UT Southwestern team IDs next-gen approach to fighting pancreatic cancer. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Turn out the lights, the party is over: Gov't finds Theranos lab poses 'immediate jeopardy to patient safety.' CNBC article | Follow @JohnCFierce

> Neos wins FDA approval for a melts-in-your-mouth take on Adderall for ADHD. Article

> The top 10 (possible) blockbusters that (might) launch this year. More

> Venetoclax grabs third FDA 'breakthrough' for blood cancer. Report

CRO News

> PRA recruits a U.K. marketing firm to help it reach more patients. Report

> In the midst of cuts, Parexel signs new research deal. More

> Parexel dims its revenue expectations despite a solid quarter. Story

> Icon launches new tech with promise to simplify adaptive trials. News

> BioClinica notches up another deal, this time with EPS. Article

Pharma Manufacturing News

> Lilly closing two animal health manufacturing plants picked up from Novatis. Article

> Baxter recalls saline, other products, contaminated by cardboard, cloth and skin. News

> Novartis revamping manufacturing after hiving off 25 plants. More

> GSK production coming up short for meningitis B vax, causing some shortages. Item

> Recipharm wrapping up its $105M deal for Indian sterile injectables maker Nitin. Article

Pharma Asia News

> India's Supreme Court allows Cipla move in Roche patent case. News

> Sino Biopharma's asset management deal drawing negative reviews. Report

> 3SBio buys a larger stake in CP Guojian Pharma for $150M. Story

> Novartis expects India's Sun to meet February U.S. generic Gleevec launch. More

> Another legal test for U.S. in case of Chinese scientists accused of stealing GSK secrets. Article

And Finally... One percent of U.S. doctors are responsible for a third of malpractice payments. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.